A 2-Stage Phase II study of panobinostat in myeloma patients with less than complete remission (CR) following high-dose chemotherapy conditioned autologous stem cell transplantation (ASCT)
Latest Information Update: 20 Aug 2021
At a glance
- Drugs Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms Pano-Mono Study
- 07 Jul 2020 Status changed from active, no longer recruiting to completed.
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 17 Dec 2018 Planned End Date changed from 15 Feb 2018 to 14 Jan 2019.